Shares of AlloVir, Inc. (ALVR) have gained 2.7% over the past four weeks to close the last trading session at $6.03, but there could still be a solid upside left in the stock if short-term price ...
AlloVir, Inc. (ALVR) closed the last trading session at $7.83, gaining 45.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall ...
As of April 24, 2023, the average one-year price target for AlloVir is 22.44. The forecasts range from a low of 16.16 to a high of $31.50. The average price target represents an increase of 544.83% ...
NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of AlloVir, Inc. (NASDAQ: ALVR) between March 22, 2022 and December 21, 2023, both ...
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of AlloVir, Inc. (NASDAQ: ALVR) and Kalaris Therapeutics is fair to AlloVir shareholders.
Apple Vision Pro, a headset-type spatial computing device, is equipped with the M2 chip and R1 chip, and allows you to experience high-quality VR (virtual space) and AR (augmented reality) by ...
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and mining exploration companies often lose money for years before finding success with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback